Literature DB >> 19027294

Tetrahydroisoquinoline amide substituted phenyl pyrazoles as selective Bcl-2 inhibitors.

John Porter1, Andrew Payne, Ben de Candole, Daniel Ford, Brian Hutchinson, Graham Trevitt, James Turner, Chloe Edwards, Clare Watkins, Ian Whitcombe, Jeremy Davis, Colin Stubberfield.   

Abstract

Anti-apoptotic Bcl-2 protects cells from apoptosis by binding to pro-apoptotic members of the Bcl-2 family thereby playing a role in tumour survival in response to chemo- or radiation therapy. We describe a series of phenyl pyrazoles that have high affinity for Bcl-2 and rationalise the observed SAR by means of an X-ray crystal structure.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19027294     DOI: 10.1016/j.bmcl.2008.10.113

Source DB:  PubMed          Journal:  Bioorg Med Chem Lett        ISSN: 0960-894X            Impact factor:   2.823


  17 in total

Review 1.  Progress in targeting the BCL-2 family of proteins.

Authors:  Thomas P Garner; Andrea Lopez; Denis E Reyna; Adam Z Spitz; Evripidis Gavathiotis
Journal:  Curr Opin Chem Biol       Date:  2017-08-17       Impact factor: 8.822

2.  Cell death and the mitochondria: therapeutic targeting of the BCL-2 family-driven pathway.

Authors:  M J Roy; A Vom; P E Czabotar; G Lessene
Journal:  Br J Pharmacol       Date:  2014-04       Impact factor: 8.739

Review 3.  Atropisomerism in medicinal chemistry: challenges and opportunities.

Authors:  Sean T Toenjes; Jeffrey L Gustafson
Journal:  Future Med Chem       Date:  2018-01-30       Impact factor: 3.808

Review 4.  From basic apoptosis discoveries to advanced selective BCL-2 family inhibitors.

Authors:  Avi Ashkenazi; Wayne J Fairbrother; Joel D Leverson; Andrew J Souers
Journal:  Nat Rev Drug Discov       Date:  2017-02-17       Impact factor: 84.694

5.  Evaluation and critical assessment of putative MCL-1 inhibitors.

Authors:  S Varadarajan; M Vogler; M Butterworth; D Dinsdale; L D Walensky; G M Cohen
Journal:  Cell Death Differ       Date:  2013-07-05       Impact factor: 15.828

6.  Selectivity by small-molecule inhibitors of protein interactions can be driven by protein surface fluctuations.

Authors:  David K Johnson; John Karanicolas
Journal:  PLoS Comput Biol       Date:  2015-02-23       Impact factor: 4.475

7.  S55746 is a novel orally active BCL-2 selective and potent inhibitor that impairs hematological tumor growth.

Authors:  Patrick Casara; James Davidson; Audrey Claperon; Gaëtane Le Toumelin-Braizat; Meike Vogler; Alain Bruno; Maïa Chanrion; Gaëlle Lysiak-Auvity; Thierry Le Diguarher; Jérôme-Benoît Starck; Ijen Chen; Neil Whitehead; Christopher Graham; Natalia Matassova; Pawel Dokurno; Christopher Pedder; Youzhen Wang; Shumei Qiu; Anne-Marie Girard; Emilie Schneider; Fabienne Gravé; Aurélie Studeny; Ghislaine Guasconi; Francesca Rocchetti; Sophie Maïga; Jean-Michel Henlin; Frédéric Colland; Laurence Kraus-Berthier; Steven Le Gouill; Martin J S Dyer; Roderick Hubbard; Mike Wood; Martine Amiot; Gerald M Cohen; John A Hickman; Erick Morris; James Murray; Olivier Geneste
Journal:  Oncotarget       Date:  2018-04-13

8.  Structures of BCL-2 in complex with venetoclax reveal the molecular basis of resistance mutations.

Authors:  Richard W Birkinshaw; Jia-Nan Gong; Cindy S Luo; Daisy Lio; Christine A White; Mary Ann Anderson; Piers Blombery; Guillaume Lessene; Ian J Majewski; Rachel Thijssen; Andrew W Roberts; David C S Huang; Peter M Colman; Peter E Czabotar
Journal:  Nat Commun       Date:  2019-06-03       Impact factor: 14.919

9.  An Intriguing Correlation Based on the Superimposition of Residue Pairs with Inhibitors that Target Protein-Protein Interfaces.

Authors:  Masakazu Nakadai; Shuta Tomida; Kazuhisa Sekimizu
Journal:  Sci Rep       Date:  2016-01-04       Impact factor: 4.379

10.  Huang-Pu-Tong-Qiao Formula Ameliorates the Hippocampus Apoptosis in Diabetic Cognitive Dysfunction Mice by Activating CREB/BDNF/TrkB Signaling Pathway.

Authors:  Shu Ye; Dao-Jun Xie; Peng Zhou; Hua-Wu Gao; Meng-Ting Zhang; Da-Bao Chen; Yun-Peng Qin; Xin Lei; Xin-Quan Li; Juan Liu; Ya-Xun Cheng; Yong-Chuan Yao; Biao Cai; Guo-Ming Shen
Journal:  Evid Based Complement Alternat Med       Date:  2021-06-09       Impact factor: 2.629

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.